glial neoplasm with differences in prognosis. 8, 9 For low-grade glial neoplasms, adverse location, tumor recurrence, or progression despite surgery require the use of other treatment modalities. 10 The optimal treatment for low-grade gliomas remains controversial in the absence of prospective randomized trials. Most patients with fibrillary low-grade astrocytomas eventually die and only approximately 15% of patients have long-term survival. 9 Post-operative external-beam radiotherapy appears to prolong survival. 11 In a randomized study of 203 consecutive adult patients with non-anaplastic, non-pilocytic astrocytomas, 83 patients (41%) had died at a follow-up six years after external-beam irradiation compared with 55% of non-treated patients. 8 Other studies of radiotherapy for low-grade gliomas also show an improved survival. [9] [10] [11] Post-radiotherapy recurrence and progression, however, are common. 8 The role of SRS for low-grade gliomas has remained incompletely defined.
Unlike implanted seeds or wafers, 13 SRS allows for non-invasive administration of focal radiation. The majority of studies on radiosurgery for low-grade gliomas are restricted by small patient numbers and limited follow-up. Indications of early results, however, are comparable to those following external-beam radiotherapy or 125 I seed implantation. In a study of 10 patients with low-grade gliomas who received radiosurgery, one patient died 66 months after treatment and nine were alive 22-82 months after treatment. 14 Barcia et al. studied 16 patients with low-grade gliomas, six of whom received conventional external fractionated radiotherapy, six of whom received fractionated stereotactic radiotherapy, and four of whom received no prior radiation. 15 In that study, tumors disappeared in eight cases and significantly decreased in size or ceased growth in five cases. Unfortunately, survival was not reported in this study. Heppner et al. conducted a retrospective review of 49 patients with low-grade gliomas, with 63-month median follow-up, and noted a median clinical progression-free survival time of 44 months and median radiological progression-free survival of 37 months. Complete radiological remission was seen in 14 patients (29%), and mortality due to tumor progression occurred in seven patients (14%) (see Figure 2) . 16 These studies, along with others (see Table 1 
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High-grade Gliomas
The role of radiosurgery in the initial treatment of malignant gliomas continues to be a subject of debate, as the use of a highly focal planned SRS boost as part of the primary management of patients with malignant gliomas. 22 In that study the one-and two-year diseasespecific survival rates measured from the date of diagnosis were 57 and 25%, respectively. 22 Other studies show similar results. For 11 patients receiving planned external-beam radiotherapy and linear accelerator (linac) radiosurgery, Buatti et al. found the median survival to be 17 months, with all patients having progression of disease within one year of radiosurgery. 23 Radiosurgery has also been explored for the treatment of recurrent malignant gliomas. In one study of 35 patients treated for recurrence of malignant gliomas, survival after radiosurgery was eight months (21 months after initial surgery). 24 For 22 patients with recurrent malignant gliomas receiving fractionated stereotactic radiotherapy (30-50Gy in six to 10 fractions), the median survival after radiotherapy was similar, at 9.8 months. 25 Finally, in a study of 86 patients having radiosurgery for recurrent malignant gliomas, the median survival was 10.2 months, and the survival after 12 and 24 months was 45 and 19%, respectively. 26 Radiosurgical modalities other than the gamma knife (see Figure 3) may also be potentially useful and beneficial for the treatment of highgrade gliomas (see Table 1 ). XRT. 31 The authors suggest that although IMRT does not improve overall survival, it may be advantageous in some scenarios due to the decreased time required for administration of radiation.
30,31
Gliomblastoma Multiforme
In spite of advances in medical and surgical treatment of gliomas, the prognosis for most patients with GBM has hardly changed in the last decade. The vast majority of patients succumb to disease within one year of diagnosis. Studies involving the role of gamma knife surgery in the setting of GBM have yielded mixed results (see Table 2 ). 20, 28, [33] [34] [35] Souhami and colleagues, reporting on behalf of the RTOG, were the first to conduct a multicenter randomized trial looking at the addition of SRS, including both gamma knife surgery and linac-based radiosurgical techniques, to standard XRT for the treatment of GBM.
SRS was used as part of the initial management of GBM in these patients, as opposed to being used as a salvage therapy. They randomly assigned 203 patients with supratentorial GBM to receive either post-operative SRS (prescription dose 15-24Gy) followed by XRT and carmustine (BiCNU ® ), or XRT and carmustine without the preceding SRS. Among the patients who were eligible to enroll in the trial, they observed no difference between the two groups with regard to the primary end-point of survival: the SRS group had a mean survival time of 13.5 months whereas the control group had a mean survival of 13.6 months. At the University of Virginia, our unpublished experience of 56 patients appears to support the use of gamma knife surgery in GBM, providing a small survival advantage. Although the results of these institutional reviews present encouraging data, the patients receiving gamma knife surgery in each series usually represent a highly selective group; in none of the series were all of the patients at an institution treated with gamma knife surgery. Therefore, one must take caution in interpreting each institution's results and realize that such results cannot necessarily be generalized.
From a theoretical standpoint, it is difficult to understand how a highly invasive tumor such as a GBM can be treated effectively with such a focused treatment as gamma knife surgery. However, it can be used to treat the largest concentration of the residual tumor or the resection cavity based upon the neuroimaging studies. It seems clear that no single treatment modality in the neuro-oncology armory is a magic bullet for such tumors and, as such, this multimodality approach (i.e. SRS, XRT, cytoreductive surgery, and chemotherapy) to
GBMs may be prudent.
Conclusions
For patients with low-and high-grade gliomas, SRS offers a precise, local administration of radiation that may result in both tumor control and prolongation of survival. Further assessment of SRS for the treatment of gliomas requires prospective, randomized clinical evaluation. n
